Inozyme Pharma Announces Dosing of First Infant with ENPP1 D

BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation,

Related Keywords

United States , Boston , Massachusetts , Philadelphia , Pennsylvania , Kurt Gunter , Matt Pera , Davidr Weber , Inozyme Pharma , Stefan Riley , Facebook , Nasdaq , Bone Health , Twitter , Corporate Communications , Division Of Endocrinology , Deficiency Program Updates , Inozyme Pharma Inc , Linkedin , Exchange Commission , Medical Director , Private Securities Litigation Reform Act , Annual Report , Region ,